Terumo Corporation · TSE:4543
Terumo — Corporate Update (May 2020)
11 slides from Terumo's corporate update, May 18, 2020
Slide 1: COVID-19 Response and Mid- to Long-term Indications
COVID-19 Response and Mid- to Long-term Indications May 18, 2020 Shinjiro Sato President and CEO Terumo Corporation
Slide 2: Basic Policy for COVID-19 Response
Basic Policy for COVID-19 Response 1. Secure associates health and safety 2. Stable supply to sustain healthcare 3. Proactive contribution to infection prevention and treatment ©TERUMO CORPORATION 2 /11
Slide 3: Current Circumstance and Operating State
Current Circumstance and Operating State Postponement of elective procedures related to Cardiac and Vascular Demand Limited decrease in demand for General Hospital and Blood and Cell Technologies Customer Access to hospitals restricted for manufacturers Access Production/ Impact on local operation d
Slide 4: Risk Management
Risk Management Careful management to prepare for two recovery scenarios • Base scenario: Recovery in the 2nd half of FY20 • Later recovery scenario: Recovery in the 1st half of FY21 Keep in mind the possibility of additional downward swings: Demand stagnation, price erosion, supply chain interrupti
Slide 5: Strong Portfolio against COVID-19 Impact
Strong Portfolio against COVID-19 Impact General Hospital and Blood and Cell Ratio of revenue from less-impacted Japan, Technologies are less impacted, and Asia, China is higher than global competitors half our business average, approx. 30% China TBCT 8% 17% Asia and Others Americas 12% 30% FY19 FY1
Slide 6: Maintained Financial Solidity for Sustainable Growth
Maintained Financial Solidity for Sustainable Growth Equity ratio Cash on hand 3.2 months 63% of sales 45% 2.2 months of sales Terumo Global med-tech Terumo Global med-tech average * average * Also having secured necessary credit availability while maintaining “AA-” rating * Source: Terumo analysis
Slide 7: Our Progress to Strengthen Operations
Our Progress to Strengthen Operations Based on our experience of Great East Japan Earthquake, Hurricane Maria, and Shipping delays at Ashitaka factory Actions taken amid the COVID-19 crisis Maximum effort for stable Global Easing of overconcentration supply of essential products optimization Capacit
Slide 8: Mid- to Long-term Thought-provoking on COVID-19
Mid- to Long-term Thought-provoking on COVID-19 Cardiac and Vascular • Quicker and simpler procedures Acceleration of less-invasive therapy • Shortened hospital stays Increase of outpatient procedure • Confident in General Hospital current Mid- • Infection prevention measures to Long-term Strict hos
Slide 9: Transformation Toward a New Normal
Transformation Toward a New Normal The awareness of customers and patients will fundamentally change. Society itself will change Paradigm shift acceleration Business model innovation in addition Healthcare expenditure control, to traditional product innovation digitalization, remote care, Promote im
Slide 10: The Terumo Purpose Is Even Clearer
The Terumo Purpose Is Even Clearer In the COVID-19 crisis, society is questioning the “purpose” of companies. The Terumo purpose is clear. Terumo has always been faithful to its group missionof “Contributing to Society through Healthcare.” Inheriting the DNA of Dr. Kitasato, the group has a long his
Slide 11: IR Contact
IR Contact Terumo Corporation Investor Relations Dept. E-mail: [email protected] Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to